Palavras Maria João, Faria Cátia, Fernandes Patrícia, Lagarto Alexandra, Ponciano Ana, Alçada Filipa, Banza Maria Jesus
Internal Medicine, Centro Hospitalar de Leiria, Leiria, PRT.
Physical Medicine and Rehabilitation, Centro Hospitalar de Leiria, Leiria, PRT.
Cureus. 2022 Feb 27;14(2):e22653. doi: 10.7759/cureus.22653. eCollection 2022 Feb.
COVID-19 poses a significantly more serious threat to adults aged 65 and above, with a higher mortality rate. This study aims to describe the outcome of COVID-19 patients in the elderly and very elderly population admitted to a tertiary care Portuguese hospital. The authors defined the elderly population (65 to 79 years) and the very elderly population (≥ 80 years).
We conducted a retrospective observational single center study in the internal medicine ward of a tertiary hospital from November 1, 2020 to January 31, 2021. All COVID-19 patients aged over 65 years were enrolled.
Of the 824 patients with SARS-CoV-2 infection, 586 (71%) were aged above 65 years. Of them, 61.7% were very elderly and 32.9% were elderly. The hospital recorded 53 (27.5%) deaths in the elderly group and 182 (46.3%) in the over-80 group. In the elderly population, only 32 patients had critical illness compared to the 79 in the very elderly group. In addition to respiratory complications, acute kidney failure and liver dysfunction were noted. In both groups, mortality was higher when there was acute kidney injury (AKI). With respect to treatment, dexamethasone and azithromycin did not show a statistically significant difference between the groups. The need for oxygen therapy over 4L/min, high-flow therapy, and mechanical invasive ventilation was related to higher mortality in both groups.
The very elderly group had a higher number of deaths compared to the elderly group due to multiple comorbidities. Respiratory failure was the most frequently occurring complication. Surprisingly, dexamethasone and azithromycin therapy did not show a statistically significant effect in both age groups despite their current widespread usage in COVID-19 treatment worldwide.
新型冠状病毒肺炎(COVID-19)对65岁及以上成年人构成的威胁要严重得多,死亡率更高。本研究旨在描述入住葡萄牙一家三级护理医院的老年和高龄COVID-19患者的治疗结果。作者将老年人群定义为65至79岁,高龄人群定义为≥80岁。
我们于2020年11月1日至2021年1月31日在一家三级医院的内科病房进行了一项回顾性观察单中心研究。纳入所有年龄超过65岁的COVID-19患者。
在824例感染严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的患者中,586例(71%)年龄在65岁以上。其中,61.7%为高龄,32.9%为老年。该医院记录老年组有53例(27.5%)死亡,80岁以上组有182例(46.3%)死亡。在老年人群中,只有32例患有危重症,而高龄组有79例。除呼吸并发症外,还发现了急性肾衰竭和肝功能障碍。在两组中,出现急性肾损伤(AKI)时死亡率更高。关于治疗,地塞米松和阿奇霉素在两组之间未显示出统计学上的显著差异。两组中,需要4L/分钟以上的氧疗、高流量治疗和有创机械通气与较高的死亡率相关。
由于多种合并症,高龄组的死亡人数比老年组更多。呼吸衰竭是最常出现的并发症。令人惊讶的是,尽管地塞米松和阿奇霉素目前在全球COVID-19治疗中广泛使用,但在两个年龄组中均未显示出统计学上的显著效果。